OX390
Addressing complex overdose emergencies
OX390 is developed by Orexo in partnership with the Biomedical Advanced Research and Development Authority, which is part of the US Department of Health and Human Services. Built on the AmorphOX® platform, OX390 features a novel formulation and route of administration designed to reverse respiratory depression caused by overdoses involving adulterated synthetic opioids, an escalating public health crisis in the US.
Substance
Atipamezole
Development phase
Preclinical
Temperature stability1
0.11% degradation after 6 months2
Administration
Nasal powder
Leverage established manufacturing processes
Yes
Partnership
BARDA
Why it matters
Traditional naloxone treatment alone is often insufficient in cases where opioids are combined with animal tranquilizers such as xylazine and medetomidine. These substances bind to different brain receptors, leaving patients vulnerable even after naloxone administration. OX390 is being developed to complement naloxone, offering a more comprehensive approach to reversing life-threatening overdoses in these complex scenarios.
Unlocking differentiation through technology
Leveraging AmorphOX, OX390 aims to deliver a stable, patient-friendly formulation that supports rapid onset and ease of administration in emergency settings. This technology enables Orexo to address critical gaps in overdose treatment while ensuring scalability and reliability for first responders.
Looking ahead
The growing prevalence of adulterated opioids underscores the urgent need for innovative solutions. OX390 represents a strategic opportunity to build on Orexo´s comprehensive experience in addiction and emergency care. Development efforts are progressing in close collaboration with BARDA, with the goal of delivering a life-saving therapy that meets the evolving challenges of the opioid crisis.
- Chemical degradation after accelerated stability studies in 40°C/75% RH.
- Preliminary data.
